Valve-in-Valve Implantation Is Possible

Original title: 5 Years Experience With Trancatheter Tranaspical Mitral Valve –in Valve Implantation for Bioprosthetic Valve Dysfunction Reference: Anson Cheung et al. J Am Coll Cardiol 2013;61:1759–66. Percutaneous valves development, first aortic and now mitral, has brought an opportunity to improve life quality and extend life for high risk non-surgical patients. 23 patients received transapical implantation in mitral<a href="https://solaci.org/en/2013/04/29/valve-in-valve-implantation-is-possible/" title="Read more" >...</a>

CoreValve versus Edwards. Equivalent results at one year

Original title: Transcatheter Aortic Valve Implantation With the Edwards SAPIEN Versus the Medtronic CoreValve Revalving System Devices. A Multicenter Collaborative Study: The PRAGMATIC Plus Initiative (Pooled-RotterdAm-Milano-Toulouse In Collaboration). Reference: Alaide Chieffo et al. J Am Coll Cardiol 2013;61:830–6. Since the introduction of percutaneous aortic valve replacement (TAVR), two devices have been widely used. For one side, the self-expanding<a href="https://solaci.org/en/2013/03/10/corevalve-versus-edwards-equivalent-results-at-one-year/" title="Read more" >...</a>

TAVI also for pure aortic insufficiency

Original title: Transcatheter Aortic Valve Implantation for Pure Severe Native Aortic Valve Regurgitation. Reference: David A. Roy et al. J Am Coll Cardiol 2013. Article in press. Percutaneous aortic valve replacement (TAVI) has become a standard treatment for patients with severe aortic stenosis and a high surgical risk. However for those patients who have pure aortic insufficiency, (failure<a href="https://solaci.org/en/2013/02/21/tavi-also-for-pure-aortic-insufficiency/" title="Read more" >...</a>

Vascular complications after valvular replacement using catheter: PARTNER trial findings

Reference: Généreux, et al, for the PARTNER Trial Investigators. JACC 2012; 60 (12):1043-62 Original title: Vascular complications after Transcatheter Aortic Valve Replacement: Insights From the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial The purpose of the study was to investigate the incidence, predictors and vascular complications impact after catheter aortic valve implantation (TAVI) in the PARTNER<a href="https://solaci.org/en/2012/10/01/vascular-complications-after-valvular-replacement-using-catheter-partner-trial-findings/" title="Read more" >...</a>

QFR Analysis of Coronary Lesions with TAVR

While transcatheter aortic valve replacement (TAVR) has shown benefits, significant coronary artery disease affects 50% or more of patients who undergo such procedure. However, it is still unclear which is the best treatment strategy or how to handle this condition. Quantitative flow ratio (QFR) could be a non-invasive option to assess the severity of coronary<a href="https://solaci.org/en/2024/06/29/qfr-analysis-of-coronary-lesions-with-tavr/" title="Read more" >...</a>

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

TAVR vs SAVR in Los Risk Patients: 10-Year Outcomes of the NOTION Trial

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Randomized studies have shown the benefits of TAVR in patients at prohibitive surgical risk, as well as high and intermediate risk.  The NOTION trial (Nordic Aortic Valve Intervention Trial) randomized patients with low risk severe AS to TAVR and<a href="https://solaci.org/en/2024/05/28/tavr-vs-savr-in-los-risk-patients-10-year-outcomes-of-the-notion-trial/" title="Read more" >...</a>

Quality of Life in Medium-Risk Patients Treated with TAVR vs SAVR

Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) have demonstrated similar outcomes in symptomatic aortic stenosis patients (at high or intermediate risk) in terms of 5-year survival. When evaluating the quality of life (QoL) of these two treatment strategies in patients with high surgical risk, there were no significant differences at 5<a href="https://solaci.org/en/2024/05/10/quality-of-life-in-medium-risk-patients-treated-with-tavr-vs-savr/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

NOTION Trial: 10 Year Outcomes, TAVR vs. SAVR in Low Risk Patients

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Randomized studies have shown the benefits of TAVR for treating inoperable patients, as well as high and intermediate risk patients.  The NOTION (Nordic Aortic Valve Intervention Trial) randomized patients with low risk severe AS to TAVR or SAVR (surgical<a href="https://solaci.org/en/2024/03/22/notion-trial-10-year-outcomes-tavr-vs-savr-in-low-risk-patients/" title="Read more" >...</a>

Guidewire Pacing and Pressure Assessment in TAVR: The SAFE-TAVI Study

Currently, the number of transcatheter aortic valve replacement (TAVR) procedures is increasing as it expands towards a lower-risk younger population. Therefore, continuous technological advancement is imperative to reduce post-procedural complications. The Food and Drug Administration (FDA) has approved the SavyWire, a preformed 0.035-gauge guidewire that can perform three essential functions: 1) it facilitates prosthesis transportation<a href="https://solaci.org/en/2024/03/20/guidewire-pacing-and-pressure-assessment-in-tavr-the-safe-tavi-study/" title="Read more" >...</a>

Post TAVR Long Term Outcomes in Patients with Chronic Inflammatory Disease

Patients suffering from immune-mediated chronic inflammatory disease (CID) face a high risk of developing heart disease, including aortic valve disease. Inflammatory vascular disease when triggered by an autoimmune condition, can prompt a harmful response leading to valve degeneration, with increased calcification and fibrosis, and the associated progression of stenosis, failure or both.  Prior research has<a href="https://solaci.org/en/2024/03/04/post-tavr-long-term-outcomes-in-patients-with-chronic-inflammatory-disease/" title="Read more" >...</a>